dupilumab (Dupixent)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

Adverse effects

Laboratory

Mechanism of action

More general terms

References

  1. Beck LA et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014 Jul 10; 371:130 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25006719 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1314768
  2. 2.0 2.1 Bachert C, Mannent L, Naclerio RM et al Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 2;315(5):469-479. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26836729
  3. 3.0 3.1 3.2 Wenzel S et al Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. April 26, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27130691 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2816%2930307-5/abstract
    Chung KF Dupilumab: a potential new treatment for severe asthma. Lancet. April 26, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27130690 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2816%2930311-7/abstract
  4. 4.0 4.1 4.2 Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 Sep 30; PMID: https://www.ncbi.nlm.nih.gov/pubmed/27690741
  5. 5.0 5.1 FDA News Release. March 28, 2017 FDA approves new eczema drug Dupixent https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549078.htm
    Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
    U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  6. 6.0 6.1 Blauvelt A et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo- controlled, phase 3 trial. Lancet 2017 May 4 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28478972 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31191-1/fulltext
  7. 7.0 7.1 7.2 Rabe KF, Nair P, Brusselle G et al Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2018; 378:2475-2485 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29782224 Free full text https://www.nejm.org/doi/full/10.1056/NEJMoa1804093
    Castro M, Corren J, Pavord ID et al Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018;378:2486-2496 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29782217 Free full text https://www.nejm.org/doi/full/10.1056/NEJMoa1804092
    Drazen JM, Harrington D. New Biologics for Asthma. N Engl J Med 2018;378:2533-2534 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29782236 Free full text https://www.nejm.org/doi/full/10.1056/NEJMe1806037
  8. 8.0 8.1 Brown T FDA Approves Dupilumab for Moderate-to-Severe Asthma Medscape - Oct 22, 2018. https://www.medscape.com/viewarticle/903761
  9. From The Medical Letter on Drugs and Therapeutics Dupilumab (Dupixent) for Asthma JAMA. 2019;321(10):1000-1001. March 12. https://jamanetwork.com/journals/jama/fullarticle/2727443
  10. 10.0 10.1 FDA News Release. June 26, 2109 FDA approves first treatment for chronic rhinosinusitis with nasal polyps. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-rhinosinusitis-nasal-polyps
    Bachert C, Han JK, Desrosiers M et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019 Sep 19; S0140-6736(19)31881-1; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31543428
    Stevens WW. A new treatment for chronic rhinosinusitis with nasal polyps. Lancet 2019 Sep 19; S0140-6736(19)32133-6; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31543427
  11. 11.0 11.1 11.2 Jenkins K Matthew J. Zirwas, MD, on Development of Psoriasis in Dupilumab-Treated AD. The incidence of new-onset psoriasis appears similar to prevalence in the general population.
    Brumfiel CM, Patel MH, Zirwas MJ Development of psoriasis during treatment with dupilumab: A systematic review. J Am Acad Dermatol. 2021 May 19:S0190-9622(21)00995-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34022319
  12. 12.0 12.1 George J First Treatment Approved for Eosinophilic Esophagitis. FDA expands dupilumab's label to treat inflammatory condition. MedPage Today May 20, 2022 https://www.medpagetoday.com/gastroenterology/generalgastroenterology/98858
    FDA News Release. May 20, 2022 FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder
  13. 13.0 13.1 Dellon ES et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med 2022 Dec 22; 387:2317. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36546624 https://www.nejm.org/doi/10.1056/NEJMoa2205982
  14. 14.0 14.1 Kearney CM et al. Comparative effectiveness of mepolizumab, benralizumab, and dupilumab among patients with difficult-to-control asthma: A multicenter retrospective propensity- matched analysis. Ann Am Thorac Soc 2024 Jun; 21:866. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38241013 PMCID: PMC11160126 (available on 2025-06-01) https://www.atsjournals.org/doi/10.1513/AnnalsATS.202306-566OC
  15. 15.0 15.1 Bachert C, Khan AH, Fokkens WJ et al. Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP. J Allergy Clin Immunol. 2024 Aug 14:S0091-6749(24)00820-0. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39151476 Free article https://www.jacionline.org/article/S0091-6749(24)00820-0/fulltext
  16. HIGHLIGHTS OF PRESCRIBING INFORMATION DUPIXENT (dupilumab) injection, for subcutaneous use https://www.regeneron.com/downloads/dupixent_fpi.pdf